Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 39.60B | 58x | CHF 560 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17% Upside | Upgrade to Pro+ | ||
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 3.67B | 34.9x | 4.31 | CHF 48.92 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.58B | -3.9x | 0.02 | CHF 28.80 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 937.02M | -231x | -3.64 | CHF 24.42 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 541.02M | 6.9x | 0.01 | CHF 44.10 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.5% Upside | Upgrade to Pro+ | |
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 315.89M | -1x | 0 | CHF 1.55 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.5% Downside | Upgrade to Pro+ | |
Bioversys Ag | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 199.84M | CHF 34.60 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 147.31M | 8.5x | 0.05 | CHF 7.38 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 123.71M | -1.9x | -0.46 | CHF 3.36 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 115.98M | 5x | 0.03 | CHF 20.20 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 36.97M | -1.8x | -0.03 | CHF 2.94 | -8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 5.70M | -1.2x | -0.01 | CHF 0.06 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |